Directorio de personas
Diego Arango Del Corro

Diego Arango Del Corro

Grado: Doctor/a


darango(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/M-5667-2016

Grupos

Publicaciones

  • Mazzolini R; Rodrigues P; Bazzocco S; Dopeso H; Ferreira AM; Mateo-Lozano S; Andretta E; Woerner SM; Alazzouzi H; Landolfi S; Hernandez-Losa J; Macaya I; Suzuki H; Ramón y Cajal S; Mooseker MS; Mariadason JM; Gebert J; Hofstra RM; Reventós J; Yamamoto H; Schwartz S; Arango D

    Brush border myosin Ia inactivation in gastric but not endometrial tumors.

    INTERNATIONAL JOURNAL OF CANCER 132 1790-1799. .

    [doi:10.1002/ijc.27856]

  • Dávalos V; Súarez-López L; Castaño J; Messent A; Abasolo I; Fernandez Y; Guerra-Moreno A; Espín E; Armengol M; Musulen E; Ariza A; Sayós J; Arango D; Schwartz S

    Human SMC2 protein, a core subunit of human condensin complex, is a novel transcriptional target of the WNT signaling pathway and a new therapeutic target.

    Journal Of Biological Chemistry 287 43472-43481. .

    [doi:10.1074/jbc.M112.428466]

  • Alhopuro P; Sammalkorpi H; Niittymäki I; Biström M; Raitila A; Saharinen J; Nousiainen K; Lehtonen HJ; Heliövaara E; Puhakka J; Tuupanen S; Sousa S; Seruca R; Ferreira AM; Hofstra RM; Mecklin JP; Järvinen H; Ristimäki A; Orntoft TF; Hautaniemi S; Arango D; Karhu A; Aaltonen LA

    Candidate driver genes in microsatellite-unstable colorectal cancer.

    INTERNATIONAL JOURNAL OF CANCER 130 1558-1566. .

    [doi:10.1002/ijc.26167]

  • Mazzolini R; Dopeso H; Mateo-Lozano S; Chang W; Rodrigues P; Bazzocco S; Alazzouzi H; Landolfi S; Hernández-Losa J; Andretta E; Alhopuro P; Espín E; Armengol M; Tabernero J; Ramón y Cajal S; Kloor M; Gebert J; Mariadason JM; Schwartz S; Aaltonen LA; Mooseker MS; Arango D

    Brush border myosin Ia has tumor suppressor activity in the intestine.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 109 1530-1535. .

    [doi:10.1073/pnas.1108411109]

  • Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D

    Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

    CLINICAL CANCER RESEARCH 16 2375-2382. .

    [doi:10.1158/1078-0432.CCR-09-3275]

  • Wilson AJ; Chueh AC; Tögel L; Corner GA; Ahmed N; Goel S; Byun DS; Nasser S; Houston MA; Jhawer M; Smartt HJ; Murray LB; Nicholas C; Heerdt BG; Arango D; Augenlicht LH; Mariadason JM

    Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.

    CANCER RESEARCH 70 609-620. .

    [doi:10.1158/0008-5472.CAN-09-2327]

  • Yuan Z; Shin J; Wilson A; Goel S; Ling YH; Ahmed N; Dopeso H; Jhawer M; Nasser S; Montagna C; Fordyce K; Augenlicht LH; Aaltonen LA; Arango D; Weber TK; Mariadason JM

    An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression.

    CANCER RESEARCH 69 7811-7818. .

    [doi:10.1158/0008-5472.CAN-09-0986]

  • Jhawer M; Goel S; Wilson AJ; Montagna C; Ling YH; Byun DS; Nasser S; Arango D; Shin J; Klampfer L; Augenlicht LH; Perez-Soler R; Soler RP; Mariadason JM

    PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

    CANCER RESEARCH 68 1953-1961. .

    [doi:10.1158/0008-5472.CAN-07-5659]

  • Wilson AJ; Byun DS; Popova N; Murray LB; L'Italien K; Sowa Y; Arango D; Velcich A; Augenlicht LH; Mariadason JM

    Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.

    Journal Of Biological Chemistry 281 13548-13558. .

    [doi:10.1074/jbc.M510023200]

  • Ropero S; Fraga MF; Ballestar E; Hamelin R; Yamamoto H; Boix-Chornet M; Caballero R; Alaminos M; Setien F; Paz MF; Herranz M; Palacios J; Arango D; Orntoft TF; Aaltonen LA; Schwartz S; Esteller M

    A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.

    Nature Genetics 38 566-569. .

    [doi:10.1038/ng1773]

  • Vanharanta S; Pollard PJ; Lehtonen HJ; Laiho P; Sjöberg J; Leminen A; Aittomäki K; Arola J; Kruhoffer M; Orntoft TF; Tomlinson IP; Kiuru M; Arango D; Aaltonen LA

    Distinct expression profile in fumarate-hydratase-deficient uterine fibroids.

    HUMAN MOLECULAR GENETICS 15 97-103. .

    [doi:10.1093/hmg/ddi431]

  • Vanharanta S; Wortham NC; Laiho P; Sjöberg J; Aittomäki K; Arola J; Tomlinson IP; Karhu A; Arango D; Aaltonen LA

    7q deletion mapping and expression profiling in uterine fibroids.

    ONCOGENE 24 6545-6554. .

    [doi:10.1038/sj.onc.1208784]

Proyectos

  • Nueva aproximación terapéutica para el cáncer colorectal.
  • EPH Receptor Signaling in Endometrial Cancer
  • Antioxidant treatment as a novel therapeutic option for microvillus inclusion disease. ARMED
  • Programa d'Impuls al Talent i l'Ocupabilitat (2021-2024)
  • Nueva estrategia terapéutica para ael cáncer gástrico basada en la modulación de la señalización de RHOA
  • Desarrollo de nanosistemas de marcaje de CXCR4 mediante radiosondas para la imagen molecular de células tumorales y del microambiente tumoral
  • Identificación de nuevos biomarcadores de respuesta a los compuestos regorafenib y TAS-102 en pacientes con cáncer colorrectal.
  • Targeting tumor microevironment by a translational multivalent nanomedicine: towards an effective anticancer combination immunotherapy